Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III-IV, Comparative, Randomized, Open-Label, Study to Evaluate Safety and Efficacy of Suspending Nucleosides From a Triple-Drug Therapy Based on Lopinavir/Ritonavir Versus Continuing Triple-Drug Therapy in HIV-Infected Subjects With Undetectable Plasma HIV Viremia for Six Months

NCT00114933 is registered in ClinicalTrials.gov with Arribas, Jose R., M.D. as lead sponsor.

NCT NCT00114933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III-IV, Comparative, Randomized, Open-Label, Study to Evaluate Safety and Efficacy of Suspending Nucleosides From a Triple-Drug Therapy Based on Lopinavir/Ritonavir Versus Continuing Triple-Drug Therapy in HIV-Infected Subjects With Undetectable Plasma HIV Viremia for Six Months
Lead sponsor
Arribas, Jose R., M.D.
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2005
Completion date
May 31, 2007
Enrollment
200
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection